BioSpace News Archive

Thermo Fisher Scientific Inc., the world leader in serving science, has completed its acquisition of MarqMetrix, a privately held developer of Raman-based spectroscopy solutions for in-line measurement.

Vistagen today announced favorable safety and tolerability data from its U.S. Phase 1 clinical trial of itruvone (PH10), the Company’s investigational rapid-onset pherine nasal spray for the treatment of major depressive disorder (MDD).

Omeros Corporation (Nasdaq: OMER), today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 23, 2023, starting at 10:00 a.m. Pacific Time.

Intrinsic Therapeutics, Inc. announced today that Cigna Healthcare has issued a positive coverage policy for the Barricaid® Bone-Anchored Annular Closure device.

DiaMedica Therapeutics Inc. today announced it has entered into definitive agreements to sell its common shares in a private placement with accredited investors.

Lumos Pharma, Inc. (NASDAQ:LUMO) is hosting today a virtual Key Opinion Leader (KOL) Webinar where Drs. Fernando Cassorla and Michael Tansey will highlight the encouraging new data and analysis on oral LUM-201 for idiopathic PGHD from the Phase 2 PK/PD OraGrowtH212 and dose-finding OraGrowtH210 Trials presented at the Endocrine Society (ENDO) Annual Meeting.

SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced it has received Institutional Review Board (IRB) approval for its Phase IIb clinical trial for SCI-110 in subjects suffering from Tourette Syndrome (“TS”).

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today highlighted recent Alport syndrome natural history data presented at the 60th ERA (European Renal Association) Congress.

Mediso has announced the Food and Drug Administration (FDA) clearance of the InterView™ FUSION and InterView™ XP multimodality (PET/SPECT/MRI/CT) image processing and reporting software which is specifically adapted for nuclear medicine and molecular imaging workflows.

Herbalife have been invited to present their scientific research at several conferences in the third quarter of 2023.